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ABSTRACT 
Menopause is a natural biological process characterized by reduction of sex hormone 
levels, namely estrogen and progesterone. The loss of estrogens appears to trigger a 
cascade of downstream events, leading to increased risk for cardiovascular diseases 
(CVD). The conjugation of the aging process and loss of estrogen during menopause 
negatively impacts lipid metabolism in the heart, resulting in increased lipotoxicity and 
the risk for cardiovascular diseases. 
Structurally similar to 17β-Estradiol, phytoestrogens (PEs), plant-derived compounds 
displaying estrogenic and/or antiestrogenic activity, demonstrate a positive impact on 
CVD in several studies. The main objective of our study was to investigate if 
coumestrol and enterodiol, two promising PEs, are able to protect the cardiac tissue 
against lipotoxicity induced by free fatty acids. Estradiol was also used, as a positive 
control. The cell line H9c2 was used as an in vitro model for cardiac cells to investigate 
palmitic acid (PA)-induced lipotoxicity and the possible protection by coumestrol and 
enterodiol. However, a new approach was used in this study, based on cell culture in a 
serum-free medium. In this context a preliminary characterization of the cells was 
performed, showing that culture in serum-free medium leads to differentiation to a 
cardiac phenotype, with the activation of autophagy possibly having a role in the 
differentiation process. 
Regarding the main hypothesis of the present work, PA-induced cardiac lipotoxicity 
was used to mimic the accumulation of free fatty acids (FFA) in cardiomyocytes. The 
protective effect of 17β-estradiol, coumestrol and enterodiol, was determined by cell 
proliferation using the Sulforhodamine (SRB) assay, mitochondrial membrane potential 
alteration by flow cytometry and finally by detecting markers for autophagy signaling 
by Western Blotting. 
The results shows a dose- and time-dependent decrease in H9c2 cell mass when 
incubated with PA, with a maximal effect obtained for 100μM. For the PEs analyzed, 
we observed that non-toxic concentrations have reduced toxicity on H9c2 
cardiomyoblasts. Moreover, we found that treatment with coumestrol significantly 
prevented the effect of PA on H9c2 cells, increasing the mitochondrial membrane 
potential when compared with cells treated with PA-treated cells. Altogether, we can 
conclude that PA is an effector of lipotoxicity and that coumestrol and enterodiol have 
xxii 
 
reduced toxicity on H9c2 cells. Furthermore, coumestrol protects against the PA 
toxicity. However, the mechanisms underlying this protection are still largely unknown.  
Since women have elevated serum fatty acids and increased risk for CVD during 
menopause, it is possible that coumestrol can be used to prevent lipotoxicity and reduce 
the risk of CVD in the menopausal women.  
 
 
Keywords: Menopause; Cardiac Lipotoxicity; Estrogens; Phytoestrogens. 
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SUMÁRIO 
A menopausa é um processo biológico natural caracterizado pela redução dos níveis 
hormonais, nomeadamente, o estrogénio e progesterona. A perda de estrogénios parece 
desencadear uma cascata de eventos, levando ao aumento do risco para doenças 
cardiovasculares. A conjugação do processo de envelhecimento e perda de estrogénio 
durante a menopausa tem um impacto negativo no metabolismo dos lípidos no coração, 
o que resulta no aumento da lipotoxicidade e portanto do risco de doenças 
cardiovasculares. 
Estruturalmente semelhantes ao 17β-estradiol, os fitoestrogénios, são compostos 
derivados de plantas que podem exibir actividade estrogénica ou anti-estrogénica, 
demostrando em vários estudos um impacto positivo nas doenças cardiovasculares. 
Assim, o principal objetivo do nosso estudo foi investigar se coumestrol e enterodiol, 
dois promissores fitoestrogénios, são eficientes em proteger o tecido cardíaco contra 
lipotoxicidade induzida por ácidos gordos livres. O Estradiol também foi usado, como 
um controlo positivo. 
A linha celular H9c2 foi usada como um modelo in vitro para células cardíacas, de 
modo a investigar a lipotoxicidade induzida pelo ácido palmítico, bem como a possível 
protecção do coumestrol e enterodiol. No entanto, uma nova abordagem foi usada no 
presente trabalho, tendo como base a cultura de células em meio isento de soro. Neste 
contexto uma caracterização preliminar das células foi realizada, evidenciando que a 
cultura em meio sem soro conduz à diferenciação de um fenótipo cardíaco, com a 
activação da autofagia possivelmente tendo um papel no processo de diferenciação. 
Em relação à principal hipótese do trabalho, a lipotoxicidade cardíaca foi induzida pelo, 
de modo a mimetizar a acumulação de ácidos gordos nos cardiomiócitos. O efeito 
protector do 17β-estradiol, coumestrol e enterodiol, foi determinado pela proliferação de 
células utilizando o ensaio de SRB, alterações no potencial mitocondrial membranar por 
citometria de fluxo e, finalmente, pela detecção de marcadores de sinalização de 
autofagia usando Western Blot. 
Os resultados mostram de uma forma dependente da dose e tempo uma diminuição no 
número de células quando incubadas com PA, com um máximo efeito máximo para 
100µM. Para os fitoestrogénios analisados, observou-se que concentrações não tóxicas 
apresentam toxicidade reduzida em cardiomioblastos. Além disso, mostrámos que o 
tratamento com coumestrol preveniu significativamente o efeito do PA nas células 
xxiv 
 
H9c2, aumentando o potencial de membrana mitocondrial, quando comparado com 
células tratadas com PA. Em conjunto, podemos concluir que o PA é um eficaz na 
lipotoxicidade e que o coumestrol e enterodiol apresentam toxicidade reduzida em 
células H9c2. Além disso, o coumestrol protege contra a toxicidade exercida pelo PA. 
No entanto, os mecanismos subjacentes a esta proteção são ainda desconhecidos.  
Uma vez que as mulheres apresentam elevados níveis de ácidos gordos no soro e um 
aumento do risco de doenças cardiovasculares durante a menopausa, é possível que o 
coumestrol possa ser utilizado para prevenir lipotoxicidade e reduzir o risco de doenças 
cardiovasculares em mulheres na menopausa. 
 
Palavras-chave: Menopausa; Lipotoxicidade cardíaca; Estrogénios;  
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1.1. The role of estrogen in woman’s life 
The menstrual cycle is generated and regulated by estrogens, steroid hormones 
mainly produced in ovaries and adrenal glands (Moreira et al., 2014; Rettberg et al., 
2014). In the female body, three forms of estrogens exist, namely estrone (E1), estradiol 
(E2) and estriol (E3) (Rettberg et al., 2014).  
Estrogens synthesis results from the conversion of cholesterol to androstenedione 
or testosterone and subsequently aromatization to estrone and estradiol in granulosa 
cells (Figure 1) (Cui et al., 2013; Porter et al., 1991). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 - Estradiol production in granulosa cells, adapted from (Cui et al., 2013). 
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The role of estrogens in the promotion of female sexual characteristics and the 
maintenance of the reproductive system has been described (Rettberg et al., 2014). In 
non-pregnant and non-menopausal women, the main circulating estrogen is 17β-
estradiol, being the most potent form of estrogen (Rettberg et al., 2014). Estrogens have 
a fundamental role in the development and functioning of several systems, including 
cardiovascular system, brain, reproductive system, skin and bone (Gibson and Saunders, 
2012; Kuiper et al., 1997; Murphy, 2011). The effects of estrogens are mediated by 
nuclear estrogens receptors (ER), namely ER-α and ER-β, localized in many cell types 
but with different distribution in whole body (Cui et al., 2013; Gibson and Saunders, 
2012). The binding of estrogens to these receptors in the cytoplasm results in their 
translocation to the nucleus, stimulating their action as transcription factors (Murphy, 
2011). Estrogen-Responsive Elements (ERE) are the specific DNA target sequences for 
the complex estrogens-ER (Moreira et al., 2014; Welboren et al., 2007). Moreover, ER 
can act through a non-genomic pathway that is based on the binding of estrogens to the 
classical and non-classical ERs present in plasma membrane, being mediated by second 
messengers (Cui et al., 2013; Moreira et al., 2014).  
 
 
1.1.1. Menopause 
In women’s life, menopause is one of the most critical periods, although being 
natural biological process resulting from aging, caused by reduction of ovarian 
hormones (Nelson, 2008; Oliveira et al., 2012). Menopause involves the end of 
menstrual cycle, and female fertility (Oliveira et al., 2012; Wylie-Rosett, 2007). 
Natural or spontaneous menopause occurs around the age of 50 and is confirmed 
by the absence of menstrual periods for 12 months, being considered non-pathological 
amenorrhea (Figure 2) (Nelson, 2008; Wylie-Rosett, 2007). 
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The phases of menopause are dynamic periods of time because these do not occur 
at any specific age (Blake, 2006; Soules et al., 2001). Normally, perimenopause starts 
around mid-to-late 40s and persist several years before the last menstrual period, for 4-5 
years (Nelson, 2008). During this phase, alterations in hormonal levels, with estrogen 
and progesterone decreasing and menstrual periods become irregular. Additionally, 
several menopausal symptoms appear (Blake, 2006; Greendale et al., 1999). The 
menopausal transition ends after 12 months of amenorrhea, and is followed by 
postmenopause (Blake, 2006; Soules et al., 2001). This phase can be divided into two 
periods: early and the late menopause. Early postmenopause usually last for 5 years and 
includes 12 months associated with final menstrual period and the following 4 years 
(Soules et al., 2001). This phase is clinically important because of the physiological 
changes and the prevalence of the symptoms experience in the early postmenopausal 
years. The late postmenopausal years extend throughout the latter years of a woman’s 
life, a period of drastic changes related with age (Blake, 2006). 
Although menopause is a process related with aging process, early or premature 
ovarian failure (POF) can occur before the age of 40 years, being disconnected from the 
aging process (Nelson, 2009; Oliveira et al., 2012). The early menopause can be due 
induced during medical interventions or surgical interventions or spontaneous (Shuster 
et al., 2010). There are several causes of POF spontaneous, including autoimmune 
disorders, genetic causes, infections or inflammatory conditions, enzyme deficiencies, 
Figure 2 - Reproductive stages in the women during aging: from menarche to postmenopausal adapted 
from (Nelson, 2008; Oliveira et al., 2012). 
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metabolic syndromes and idiopathic (Beck-Peccoz and Persani, 2006; Shuster et al., 
2010).  
All women undergo menopause, but their experience may be different, depending 
on their lifestyle and/or genetic information. Menopause symptoms usually include: 
vasomotor symptoms (hot flashes), depressed mood, sleep disturbances, sexual 
concerns or problems, cognitive symptoms, vaginal dryness and urinary incontinence 
(Blake, 2006; Moreira et al., 2014). 
Regarding hot flashes, they are thought to be related with the withdrawal of 
estrogens and the resulting vasomotor instability, in which leads to a sensation of 
warmth in the face, neck and chest and perspiration (Greendale et al., 1999; Samsioe et 
al., 2006). These symptoms are usually associated with anxiety, irritability, sweating, 
palpitations and panic. If all these symptoms continue for months, chronically disturbed 
sleep may occur, which may lead to a cognitive deficits (Samsioe et al., 2006). The 
cause for vasomotor symptoms is not completely understood.  
Besides hot flashes, dyspareunia, vaginal dryness, itching, and irritation resulting 
from vaginal atrophy, can be experienced by women during menopause (Greendale et 
al., 1999; Samsioe et al., 2006). Also, due to loss of estrogens, the vaginal pH changes 
from acid to neutral and vaginal flow blood become reduced (Greendale et al., 1999).  
 
 
1.1.2. Menopause and Health Problems  
The menopause condition is also accompanied with more severe complications, 
including increased cardiovascular risk, osteoporosis and body weight gain due of 
changes in hormone levels and aging (Carr, 2003; Oliveira et al., 2012). During aging, 
the metabolic rate decreases, which justifies that after menopause an increase in body 
weight and visceral adipose tissue accumulation occurs because of the ovarian hormone 
withdrawal (Babaei et al., 2010; Oliveira et al., 2012). An increase in visceral adipose 
tissue is thought to be related with various metabolic syndromes such as insulin 
resistance, dyslipidemia, hypertension, prothrombotic, and proinflammatory states 
(Barros and Gustafsson, 2011; Carr, 2003). The risk of cardiovascular disease (CVD) 
associated to the metabolic syndrome appears to be high in women, and it is probable 
that the most cardiovascular events in women are related to the metabolic syndrome 
(Carr, 2003). 
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1.1.3. Cardiovascular disease in women during menopause  
Cardiovascular disease is a multifactorial disease and is influenced by different 
factors, such as bad lifestyle that includes inappropriate diet, sedentary life, smoking 
and drinking as well as aging, menopause and genotype.  
Cardiovascular diseases include coronary heart disease, myocardial infarction, 
heart failure, and coronary death (Stevenson, 2009). Premenopausal women appear to 
be protected from CVD compared with men of similar age. After menopause, CVD risk 
increases and postmenopausal women have the same risk for this disease as do men 
which may be related to the substantial metabolic changes that occur in women 
transition from premenopause to postmenopause (Barros and Gustafsson, 2011; Carr, 
2003; Prelevic and Jacobs, 1997). Still, women who experience a premature menopause 
are more susceptible to certain health problems, such as osteoporosis and heart diseases 
because these women spend more time in their lives without the benefits of estrogens 
(Nelson, 2009; Oliveira et al., 2012; Shuster et al., 2010).  
The decline in estrogen associated with menopause leads to an increase in visceral 
fat mass, lipid accumulation and a reduced use of lipids, which increases the risk for 
developing CVDs and insulin resistance (Barros and Gustafsson, 2011; Stevenson, 
2009). In conclusion, the removal of estrogens during induced or natural menopause 
leads to several complications, which may involve alterations of lipid metabolism that 
sometimes results in increased cardiovascular risk (Chen, 2006). 
Another factor that can promote CVD is increased oxidative stress. The classical 
definition of oxidative stress involves an imbalance between reactants and antioxidants. 
Increases in reactive oxygen species causes damage to lipoproteins, lipids, DNA, 
proteins and oxidative stress-induced modifications of these molecules have been 
implicated in many disease pathways such as CVD (Strobel et al., 2011; 
Wattanapitayakula and Bauerb, 2001). Oxidative stress is believed to play a significant 
role in the initiation and progression of atherosclerosis. Lipid peroxidation occurs 
mostly in polyunsaturated fatty acids because they of the greater number of hydrogen 
chains, being more susceptible to oxidation. The process of lipid peroxidation can affect 
membrane fluidity, functioning, permeability, electron potential and the transport of 
metabolites across membranes (Strobel et al., 2011). As mentioned above, 
premenopausal women have decreased risk of heart disease compared with men but 
after menopause the risk of CVD in women increases. This increase of CVD may be 
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caused by increased levels of lipid peroxidation. In agreement, post-menopausal women 
exhibit higher levels of lipid peroxidation and therefore increased risk of CVD 
(Castelao and Gago-Dominguez, 2008). 
It still remains unclear if the type of menopause (surgical or spontaneous) 
influences cardiovascular risk in women. However, the Nurses’ Health Study (NHS) 
demonstrated that women with a natural menopause and who had never taken 
postmenopausal estrogen had no increased risk of coronary heart disease compared to 
premenopausal women. Also, women with a natural menopause who were being treated 
with estrogens also showed no difference in terms of CVD risk. In contrast, participants 
reporting a bilateral oophorectomy had a 2-fold increased risk if they did not use 
postmenopausal estrogen (Barrett-Connor, 2013; Ventura-Clapier et al., 2011). 
However, it is important to mention that aging per se has more impact than menopause 
for CVD risk factors. 
 
 
1.1.4. Cardiac Mitochondrial Fatty Acid Beta-Oxidation during Menopause 
The heart is one of the organs of the body with the highest energy requirement, 
necessary for muscle contraction. The heart is considered an omnivorous organ, using 
several substrates for energy generation, such fatty acids, carbohydrates, ketone bodies, 
lactate and even amino acids. However, fatty acids are the preferred substrate (Ventura-
Clapier et al., 2011). One fundamental characteristic of the heart is that this organ is 
metabolic flexible which is the ability to respond to changing substrate availability, 
circulating hormones, coronary flow, and fuel metabolism by choosing the right 
substrate at the right moment. So, impaired substrate metabolism leads to contractile 
dysfunction and cardiac remodeling characteristic of heart failure (Ventura-Clapier et 
al., 2011). 
Mitochondrial oxidation of fatty acids is the major source of energy in the adult 
healthy heart (Kienesberger et al., 2013). Fatty acids (FA) can be transported in the 
plasma as free fatty acids (FFAs), including saturated and unsaturated FFAs. These are 
the major energy source in human body during periods of starvation or prolonged 
endurance exercise and are released mainly from adipose tissue by lipolysis of 
triglycerides (Rial et al., 2010; Yuan et al., 2013). 
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 Under physiological conditions, fatty acids are largely bound to albumin or as a 
part of triacylglycerol (TAG) contained in chylomicrons or very-low-density 
lipoproteins (VLDLs) which are hydrolyzed by lipoprotein lipase (LPL) (Kienesberger 
et al., 2013).  
Fatty acid beta-oxidation is very important in the context of energy, adenosine 
triphosphate (ATP) production in the heart and skeletal muscle (Eaton  et al., 1996). 
Beta-oxidation is different for short-chain, medium-chain fatty acids, and long-chain 
fatty acids because the mitochondrial membrane is not permeable to long-chain fatty 
acids. Therefore, short-chain and medium-chain fatty acids of less than 10 carbon atoms 
can cross both the outer and inner mitochondrial membranes and enter the 
mitochondrial matrix after activation into their CoA esters, to which beta-oxidation 
follows (Darras and Friedman, 2000). Long-chain fatty acids, after entering 
cardiomyocytes, are converted to CoA esters, through the action of fatty acyl CoA 
synthase (FACS). The inner mitochondrial membrane is also impermeable to the CoA 
thioesters, and so these are subsequently bound to carnitine by the enzyme carnitine 
palmitoyl transferase I (CPT I), located on the inner side of the outer mitochondrial 
membrane, forming acylcarnitine. This molecule is then transferred across the inner 
mitochondrial membrane by carnitine acylcarnitine translocase (CAT). In the 
mitochondrial matrix, acylcarnitine is converted back to the acyl-CoA derivative and 
carnitine by CPT II, which is localized on the inner side of the inner mitochondrial 
membrane. Finally, the long-chain acyl-CoA derivative enters the beta-oxidation 
pathway (Figure 3) (Darras and Friedman, 2000). 
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Long-chain fatty acyl CoA can be used for the synthesis of intermediates, such as 
TAG, diacylglycerol (DAG) and ceramide. These intermediates are stored and/or 
channeled to different biosynthetic pathways, namely biomembrane synthesis (Li et al., 
2010; Lopaschuk  et al., 2010). When alterations of normal fatty acid homeostasis 
occur, for example, during high FFA levels in the plasma, these intermediates can 
accumulate in cells. Depending on the tissue, this accumulation can have different 
effects. Excessive accumulation of TAG in non-adipocyte tissues can result on 
impairment of insulin signaling in the liver and skeletal muscle (van Herpen and 
Schrauwen-Hinderling, 2008), as well as apoptosis in the heart (Borradaile and 
Figure 3 - Transport of fatty acids from the cytoplasm to the mitochondrial matrix for oxidation, adapted 
from (Darras and Friedman, 2000; Lopaschuk et al., 2010; Oliveira et al., 2012). Abbreviations: VLDL - 
very-low-density lipoproteins; TAG – triacylglycerol; LPL - lipoprotein lipase; FATP - fatty acid 
transport protein; FACS - fatty acyl CoA synthase; ATP - adenosine triphosphate; AMP - adenosine 
monophosphate; CPTI - carnitine palmitoyl transferase I; CPTII - carnitine palmitoyl transferase II; CAT 
- carnitine acylcarnitine translocase. 
 11 
 
Schaffer, 2005; Li et al., 2010). Diacylglycerol is also thought to be involved in 
apoptosis and in triggering insulin resistance (Wende and Abel, 2010). Moreover, 
ceramide increases apoptotic signaling in several tissues, being involved in the 
triggering of the mitochondrial permeability transition pore (MPTP) and outer-
membrane permeabilization. Furthermore, FA per se causes the release of apoptogenic 
factors from mitochondria, consequently causing mitochondrial dysfunction and cell 
death (Rial et al., 2010). The failure of mitochondrial bioenergetics destabilizes fatty 
acid metabolism that may result in the accumulation of fatty acyl-CoA esters in the 
cytosol of cardiomyocytes. This, in turn, leads to increased synthesis of the 
intermediates previously mentioned, TAG, DAG and ceramide, leading to cell death, 
thus working in a positive feedback cycle.  
Furthermore, exposure to saturated fatty acid but not to unsaturated fatty acid 
triggers apoptosis in cell culture. Palmitic acid (C16:0) (PA) induces apoptosis via de 
novo ceramide formation and activation of the mitochondrial apoptotic pathway (Dyntar 
et al., 2001). Incubation of adult rat cardiomyocytes with PA damages contractile 
elements and cytoskeleton (Dyntar et al., 2001). It is apparent that the saturated FFAs in 
the human body may be involved in the development of many chronic diseases, such as 
obesity, diabetes and cardiovascular diseases (Yuan et al., 2013). As apoptosis of 
cardiomyocytes plays a central role in heart failure (Dyntar et al., 2001), a balance 
between FFA cell uptake and metabolism is necessary. Moreover, there must be an 
efficient transport of fatty acyl-CoA for to beta-oxidation and subsequent energy 
production.  
Aging is a biological process characterized by a general and progressive decline in 
physiological functions that affects many tissues. For example, mitochondrial function 
in the heart decreases with aging (Paradies et al., 2010; Petrosillo et al., 2009). 
Decreased mitochondrial function occurs with aging, affecting both the bioenergetics 
and several signaling pathways to and from mitochondria.  
Figure 4 shows the rationale proposed by Oliveira and colleagues (Oliveira et al., 
2012), for the conjugation of aging process and hormonal alterations resulting from 
menopause, leading to a degradation of mitochondrial capacity in the heart. These 
alterations are associated with a progressive decrease in lipid oxidation in mitochondria 
and increased lipid storage in adipocytes. Moreover, the formation of fatty acyl 
intermediates, such as DAG, TAG and ceramide in the cytosol of cardiomyocytes may 
causes myocardial lipotoxicity and result in the activation of apoptotic signaling.  
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Therefore, cardiovascular risk increases under these circumstances. Estradiol 
increases fatty acid oxidation by mitochondria preventing the potential accumulation of 
deleterious metabolites and increasing fatty acid-derived mitochondrial ATP production 
(Figure 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 -Specific mitochondrial alterations in the menopausal women. (A) The conjugation of aging 
process and hormonal alterations caused by menopause leads to an impaired fatty acids metabolism 
contributing to increased fatty acids CoA and also fatty acyl intermediates, such as DAG, TAG and 
ceramide in the cytosol of cardiomyocytes, which in turn causes lipotoxicity. Under these conditions, 
cardiovascular risk increases. (B) Estradiol (green arrows) may act on improvement of fatty acid oxidation 
in the heart, decreasing the levels of the fatty acyl intermediates and consequently lipotoxicity, preventing 
cardiovascular diseases. (Adapted from (Oliveira et al., 2012)). Abbreviations: DAG- diacylglycerol; TAG 
- triacylglycerol; ATP - adenosine triphosphate. 
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Pelzer and collaborators (Pelzer et al., 2000) demonstrated that apoptosis in 
cardiomyocytes can be prevented by physiological levels of 17β-estradiol, preventing 
the loss of cardiomyocytes in heart failure. Other reports demonstrated that estrogen 
reduces cardiac hypertrophy and also reduces infarct size, improve contractile function 
after ischemia/reperfusion (Murphy, 2011). Also Viña and colleagues (Viña et al., 
2005) demonstrated that estrogen reduces mitochondrial hydrogen peroxide (H2O2) 
production by up-regulating the expression of antioxidant enzymes, such as 
mitochondrial superoxide dismutase (Mn-SOD) and glutathione peroxidase (GPX), 
which are longevity-associated enzymes.  
Thus, it is evident that sex hormones have an important role in the regulation of 
lipid metabolism and consequently in the protection against CVD mediated by different 
mechanisms. 
 
 
1.1.5. Hormone Replacement Therapy 
The menopausal women present alterations in metabolism and cardiovascular 
function. Currently, hormone replacement therapy (HRT) is the most used approach to 
prevent menopausal symptoms, being based on the administration exogenous hormones. 
The most commonly used hormones are estrogen and progestin used together, but 
estrogen can also be used alone in women without uterus. Estrogen-progestin therapy is 
prescribed for women who have not had hysterectomies and thus still have uterus 
because the progestin protects the endometrium from the harmful effects of estrogen 
(Nelson, 2008).  
The effects of HRT are believed to be mostly beneficial, owing to a reduction in 
risk of cardiovascular disease, osteoporosis, and colon cancer (Schierbeck et al., 2012). 
Schierbeck and colleagues (Schierbeck et al., 2012) showed that when HRT was started 
early in postmenopause, a significantly decreased risk of composed endpoint of death, 
heart failure, or myocardial infarction was observed. These results suggest that HRT, 
when initiated in recent menopausal women and continued for a prolonged duration 
does not increase or provoke adverse cardiovascular events. A previous study showed 
that HRT modulates lipid homeostasis; postmenopausal women that received HRT 
presented decreased levels of PA and increased levels of oleic acid (Piperi et al., 2005). 
However, HRT has been subject to much discussion and speculation. In 2002, the 
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Women’s Health Initiative (WHI) showed that the use of Estrogen plus Progestin does 
not present cardiovascular benefit and suggested in fact an increased risk in breast 
cancer. Furthermore, the treatment with estrogen alone had no effect on CVD risk 
(Writing Group for the Women’s Health Initiative Investigators, 2002). Because of this 
study, women started searching for safer alternatives to HRT.  
Despite the controversy surrounding HRT, it is true that the current therapy is still 
the folder standard therapy to decrease the pathophysiology of menopause. 
Nevertheless, the use of phytoestrogens as alternatives to HRT has been increasing. 
 
 
1.1.6. Phytoestrogens 
An alternative to the classical HRT involves phytoestrogens (PEs), natural, plant-
derived, estradiol mimetics. Phytoestrogens are plant-derived compounds that are 
structurally or functionally similar to 17β-estradiol and therefore exhibit some 
estrogenic and/or antiestrogenic activity, although being less potent than natural 
hormones (Borrelli and Ernst, 2010; Eden, 2012). There are four main classes of 
phytoestrogens: isoflavones, lignans, coumestans and stilbenoids (Figure 5) (Borrelli 
and Ernst, 2010). 
The main type that has been therapeutically given to menopausal women involves 
isoflavones because are the most abundant and studied. In the human diet, 
phytoestrogens are mostly found in legumes such as soybean, chickpeas, alfalfa and red 
clover (Eden, 2012). In plants, isoflavones are mainly present as inactive glycosides: 
genistin and daidzin  (Lissin and Cooke, 2000). The majority of phytoestrogens are 
introduced into the diet as inactive compounds. After consumption, a complex 
enzymatic conversion occurs, with the sugar residue being removed in the 
gastrointestinal tract, resulting in the formation of compounds with a steroidal structure 
similar to estrogens (Albertazzi and Purdie, 2008; Fitzpatrick, 2008). 
The class of coumestans and stilbenoids are less abundant in diet and so these 
compounds have been less studied (Dixon, 2004). Coumestrol belongs to the class 
coumestans and has higher affinity for estrogens receptors, exhibiting stronger 
estrogenic activity (Tinwell et al., 2000). Furthermore, coumestrol has direct influence 
on liver metabolism, through an increase in lipid synthesis and glycogen metabolism in 
an independent mechanism from its estrogenicity (Nogowski, 1999). The main source 
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of coumestrol is Medicago sativa (alfalfa), Trifolium pratense (red clover) and 
soybeans. The most well-known stilbenoid is resveratrol that has been demonstrated to 
have antioxidant properties, with its main source of resveratrol being the skin of red 
grapes and red wine (Khan et al., 2008).  
Lignans are biotransformed by intestinal microflora and converted to hormone-
like compounds with weak estrogenic activity (enterodiol and enterolactone). Lignans 
exist in plants as glycosides stored in vacuoles (Adlercreutz, 2007).  
 
 
 Figure 5 - The main classes of phytoestrogens. 
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The phenolic ring present in phytoestrogens is one of the prerequisites for the 
bonding to ER and therefore can work as agonists or antagonists of ERs. Several factors 
influences the cellular effects of PEs, such as presence or absence of endogenous 
estrogens, the target tissue and concentration (Setchel, 1998).  
Genistein is the most popular PE and is effective as an agonist of both ER at 
concentrations lower that 10µM (Miyazaki, 2004; Sun et al., 2012). The efficacy of 
these substances can be explained by their specific binding to the estrogen receptor. 
There are two types of ER: ER-α and ER-β, with PEs binding with higher affinity to 
ER-β than to Er-α (Terzic et al., 2012). Thus, PEs show positive estrogenic effects 
mainly in tissues expressing basically ER-β, such as the bone or the cardiovascular 
system. 
Relatively to symptoms PEs have shown satisfactory results (Jacobs et al., 2009). 
It has been reported that several PEs can be cardioprotective during the transition to 
menopause (Song et al., 2007). After treatment with 35 mg isoflavones, osteoprotection, 
decreased CVD risk, attenuation of hot flushes and night sweats in treated women were 
already reported (Guojun et al., 2007). One study with lyophilized grape powder in 
postmenopausal women showed alterations in lipoprotein metabolism, oxidative stress, 
and inflammatory markers (Zern et al., 2005). Phytoestrogens derived from both, soy 
and red clover, were shown to have a positive metabolic effect on serum lipids of 
postmenopausal women. So both sources of PEs can be equally used (Terzic et al., 
2012).  
 
 
1.2. H9c2 cell line as a model for cardiac cells 
The H9c2 cell line was derived from embryonic rat heart and isolated by the 
method of selective serial passage (Kimes and Brandt, 1976). This cell line has been 
used as in vitro model for both skeletal and cardiac muscle due their morphological 
features and electrophysiological characteristics (Menard et al., 1999).  
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One advantage of this cell line is the ability to differentiate and acquire both a 
phenotype of skeletal muscle such as the heart muscle, depending on the stimulus 
(Menard et al., 1999). Upon reduction of media serum concentration, H9c2 cell line can 
be differentiated from mono-nucleated myoblasts to myotubes (Hescheler et al., 1991).  
Menard and colleagues (Menard et al., 1999) demonstrated that the treatment of 
these cells with all-trans retinoic acid (RA) leads to cell differentiation to an adult 
cardiac muscle phenotype, as seen by specific differentiation markers. Thus, these 
findings support the possibility that RA may inhibit myogenic differentiation of these 
cells providing the cardiac phenotype (Figure 7) (Menard et al., 1999). 
Figure 6 – An example of H9c2 cells incubated with tetramethylrhodamine, methyl ester 
(TMRM) and Hoechst 33342. The images were obtained using a Nikon C-1 laser scanning 
confocal microscope equipped with 60x Plan Apo 1.4 NA oil immersion DIC objective. TMRM 
signal was acquired using a green He-Ne laser and the Hoechst 33342 signal was obtained by 
using a violet diode laser. Differential interference contrast (DIC) images using the confocal 
microscope were collected using the air-cooled argon laser and the appropriate detector. Images 
were captured using the Nikon EZ-C1 software (version 2.01).  
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During muscle differentiation some typical features appears, including fusion of 
myoblast to myotubes and expression of myogenic transcription factors (Chun et al., 
2000), calcium channels proteins (Menard et al., 1999). 
 In the same line of investigation, other authors also reported that the reduction of 
serum to 1% supplemented with RA, leads into a long and multinucleated 
cardiomyocytes with higher content in troponin T, phosphorylated troponin I, and 
ventricular myosin light chain (MLC2V), all markers of cardiac differentiation, in H9c2 
differentiated cells (Branco et al., 2011; Pereira et al., 2011). On the other hand, only 
the reduction of serum to 1% conducts to predominantly skeletal muscle phenotype, 
presenting multinucleated skeletal myotubes and a reduced content in cardiac markers 
(Apostolova et al., 1999; Branco et al., 2011; Pereira et al., 2011). 
Figure 7 - Schematic representation of the differentiation process of H9c2 myoblasts. After 
reduction of media serum to 1%, cells differentiate in skeletal muscle cells. However, 
supplementing with RA induces differentiation into cardiac muscle cells. Abbreviations: DMEM - 
Dulbecco's modified Eagle's medium; FBS- fetal bovine serum; RA - retinoic acid. 
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 Thus, H9c2 cardiomyoblasts are a good cellular model and an attractive tool to a 
cardiac surrogate, due to it differentiation potential. Several studies have been used in 
this cell line to investigate the cardiac toxicity or even to the protection of several 
compounds, including resveratrol, doxorubicin (DOX) (Branco et al., 2012; Sardao et 
al., 2009b) and isoproterenol (Branco et al., 2011; Branco et al., 2013). Nevertheless, 
several studies gave little importance to the differentiation state of the H9c2 cells, but it 
is known that the susceptibility to different agents is different between undifferentiated 
and differentiated cells (Branco et al., 2011). During differentiation process the H9c2 
metabolism is also altered, involving different effects on both cell populations when 
compounds interacts and modulate cell metabolism (Pereira et al., 2011). Another 
characteristic of H9c2 cardiomyoblasts is the expression of ERs, more concretely ER-β 
(Urata et al., 2006), which is a feature essential for the main goal of the present thesis. 
 Due to all the reasons refereed above, we consider the H9c2 cell line a good 
cellular model to study the protection of PEs against cardiac lipotoxicity, although the 
in vitro differentiation can cause stress to the cells activating different signaling 
pathways that can lead at autophagic processes.  
 
 
1.2.1. Autophagy Pathway  
 The autophagy (“to eat oneself”) is a process that involves the cellular 
degradative pathways, being the major regulated mechanism an also the only one 
degradative pathway of the organelles (Levine and Yuan, 2005). There are three 
different autophagic pathways identified, namely macroautophagy, microautophagy and 
chaperone mediated autophagy (Levine and Kroemer, 2008), but in the present thesis 
we will focus only on macroautophagy (hereafter referred to as autophagy). 
 In normal conditions, autophagy occurs at low basal levels in order to maintain 
cell homeostasis, namely, cytoplasmic and organelle turnover (Klionsky, 2000; Levine 
and Kroemer, 2008; Levine and Yuan, 2005). However, cell starvation or deprivation of 
growth nutrients can lead to an induction of autophagy, providing the energy required 
for cell survival (Ichimura and Komatsu, 2010; Klionsky, 2000). 
 During autophagy, the formation of an isolation membrane (vesicle nucleation), 
which sequesters cytoplasmic material including mitochondria, endoplasmic reticulum, 
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and ribosomes (vesicle elongation) occurs. Afterwards, the edges of the membrane fuse 
and form a structure with a double membrane, designed by autophagosome. Then, the 
autophagosome fuses with lysosome leading to autolysosome formation, where the 
sequestered material is degraded and recycled. The degradation of the sequestered 
material generates fatty acids or aminoacids, which in turn can be used by mitochondria 
for the ATP production, provided cell survival (Figure 8) (Ichimura and Komatsu, 
2010; Levine and Kroemer, 2008; Levine and Yuan, 2005). 
 
 
As mentioned above, the initiation of the autophagic pathway is characterized by 
the presence of an induction phase, which is triggered by cellular stresses. Considering 
the starvation condition, autophagy can be induced by inhibition of mechanistic target 
of rapamycin (mTOR), the major autophagy inhibitory signal (Kang et al., 2011; 
Klionsky, 2000; Levine and Kroemer, 2008). The complex UNC-51–like kinase 1 
(ULK1), autophagy related gene (ATG13), FIP200, and ATG101 can be activated due 
Figure 8 - The macroautophagy pathway, during a starvation or in growth nutrient deprivation 
condition, adapted from (Levine and Kroemer, 2008; Levine and Yuan, 2005). 
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to mTOR inhibition, allowing the initiation of autophagy signaling. After activation of 
the ULK1 complex, it can regulate the class III phosphatidylinositol 3-kinase (PI3K) 
complex, which includes Beclin-1 (Mizushima and Komatsu, 2011). Moreover, the 
stimulation of this complex leads to phosphatidylinositol-3-phosphate (PI3P) 
generation, contributing to vesicle nucleation and serves as signal to the recruitment of 
proteins required for vesicle elongation (Sinha and Levine, 2008). There are two 
ubiquitin-like conjugation systems, such as the ATG5-ATG12 and the light chain 3 
(LC3), which are required for the autophagosomal elongation (Choi et al., 2013). 
 Regarding the LC3 pathway, firstly it is proteolyzed in its C-terminus by the 
cysteine protease ATG4 and afterwards it is activated by the E1 ubiquitin-like enzyme 
ATG7, being further transferred to the E2 ubiquitin-like enzyme ATG3 allowing 
phosphatidyl ethanolamine (PE) connection to LC3-I that origin LC3-II that associates 
to the autophagosomal membrane (Choi et al., 2013; Levine and Kroemer, 2008). This 
conversion, LC3-I into LC3-II is a key regulatory step in autophagosome formation. 
 In the final step, the degradation of autophagosomal contents is carried out by 
lysosomal acid hydrolases, being released for metabolic recycling (Choi et al., 2013). 
Notwithstanding, selective mechanisms were described (Ichimura and Komatsu, 2010; 
Komatsu and Ichimura, 2010), taking advantage of p62/SQSTM1 (sequestosome 1). 
This interacts with LC3-II, being transported into the autophagosome (Ichimura and 
Komatsu, 2010), acting as selective autophagy substrate and cargo receptors for 
degradation of ubiquitinated substrates. 
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2. HYPOTHESIS AND OBJECTIVE 
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Menopausal women have increased incidence of CVD because estrogen loss 
negatively impacts lipid metabolism and cardiovascular function (Rosano et al., 2007). 
Some studies with PEs have demonstrated some effects on the symptoms and 
complications of menopause, such as osteoporosis and cardiovascular disease (Beck et 
al., 2005). For that reason, the main hypothesis of the present work is that coumestrol 
and enterodiol, two promising PEs, are able to protect cardiac tissue against cardiac 
lipotoxicity induced by free fatty acids. 
In this context, the H9c2 cell line, an in vitro model for cardiac cells and PA as a 
induced-lipotoxicity agent were used in the present work. Nevertheless, for this study an 
alternative protocol for cell culture was used, namely, the use of serum-free medium 
without phenol-red, a pH indicator present in culture media. Phenol-red can mimic the 
biological effects of estradiol in estrogen-sensitive cells because it binds to estrogen 
receptors (Berthois et al., 1986; Welshons et al., 1988), masking the effect of estradiol 
or even of PEs and leading to underestimation of the response potential of cells. On the 
other hand, serum, specifically Fetal Bovine Serum (FBS), contains hormonal factors 
and other growth factors which stimulate cell proliferation; further we are generally not 
aware of the real composition of FBS. So, this is disadvantage because it may lead to 
underestimation of the results. 
Concerning these evidences, the first step of the present work was the 
characterization of H9c2 cells in absence of serum. Given the literature (Branco et al., 
2011; Menard et al., 1999), we hypothesize that H9c2 cardiomyoblasts cultured in 
absence of serum can acquire a cardiac phenotype. In order to characterize the cell line, 
cardiac markers were evaluated. Furthermore, autophagy signaling was assessed due to 
its occurrence during cell starving and also due to their role in cell differentiation 
(McMillan and Quadrilatero, 2014; Mizushima and Levine, 2010). 
 
Regarding the main aim of this project, it can be divided in different experimental 
objectives: 
1. The cytotoxicity evaluation of PA using different concentrations  
 and cytotoxicity of the selected PEs; 
2. The evaluation of the protective effects of PEs against PA by  several 
parameters including cell proliferation, mitochondrial alterations and 
autophagy signaling markers. 
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 The study of the protective effects of PEs in cardiac cells is important because it 
may allow design new strategies to minimize the pathologies associated with 
menopause, including CVD.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
3. MATERIAL AND METHODS 
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3.1. Reagents 
The reagents for cell culture, such as Dulbecco’s modified Eagle’s medium - high 
glucose (DMEM-HG) (D5648), Dulbecco’s modified Eagle’s medium (D5030), L-
glutamine, glucose, sodium bicarbonate, taurine (Catalog #T8691), creatine (Catalog 
#C0780),  L- carnitine, insulin-transferrin-sodium selenite (ITS) (I3146),  bovine serum 
albumin (BSA) (Catalog #A1595), hydrocortisone (Catalog #H0135), 
dimethylsulphoxide (DMSO), 17beta-estradiol, enterodiol, coumestrol, sodium 
palmitate, BSA free fatty acid and phenylmethylsulfonyl fluoride (PMSF), 
sulforhodamine B (SRB) were obtained by Sigma (St. Louis, MO, USA). FBS and 
0.05% Trypsin–EDTA were purchased from Gibco-Invitrogen (Grand Island, NY). Cell 
lysis buffer (Catalog #9803) was purchased from Cell Signaling (Danvers, MA, USA). 
Additionally, the reagents used for Western Blot, including, nonfat dry milk (Catalog 
#170-6404), Tris-HCl, 0.5M pH 6.8, 1.5 M Tris pH 8.8, sodium dodecyl sulfate (SDS) 
and acrylamide were purchased from BioRad (Hercules, California, USA) Also, 
tetramethylethylenediamine (TEMED) and protein marker (Catalog #MB17601) were 
obtained by Nzytech (Lisboa, Portugal). 
 
3.2. Preparation of palmitic acid/BSA complexes  
Palmitate has a lower solubility in aqueous solutions and thus its careful 
preparation is a critical step for cell studies that involves the utilization of this 
compound. Accordingly, BSA has been used as a vehicle, and stabilizing agent, for 
insoluble fatty acids. The conjugation of palmitate to BSA allows cells to absorb and 
use palmitate.  
A 6:1 molar ratio palmitate:BSA was used, with concentrations of 5mM palmitate 
and 0.83mM BSA solution. Firstly, a 1.66mM BSA solution in 150mM sodium chloride 
(NaCl) was prepared. In this step BSA was added to pre-warmed NaCl solution while 
stirring constantly allowing to dissolve BSA. Then, 10mM PA solution was prepared in 
150mM NaCl solution at 70 °C while stirring, to help in the solubilization. Finally, the 
conjugation of palmitate and BSA was performed by transferring 50ml of 70 °C 
palmitate solution to 50ml of BSA solution while stirring at 37 °C during 1 hour. After 
this, the pH of the solution was checked and adjusted to 7.4 with 1N sodium hydroxide 
(NaOH) and the solution was filtered. Aliquots were kept frozen at -80 °C. The 
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remaining BSA solution was diluted with 50ml of 150mM NaCl solution to make a 
0.83mM stock and was filtered and aliquots were freeze at -80 °C. 
 
3.3. Cell line and culture conditions 
The H9c2 cardiomyoblasts, derived from embryonic rat heart were purchased 
from ATCC (Manassas, VA; catalog # CRL – 1446), stored frozen in liquid nitrogen 
vapor phase and expanded following manufacturer’s instructions.  
For the present study, cells were cultured in DMEM-HG supplemented with 
1.5g/L sodium bicarbonate, 10% of FBS at 37 °C in a humidified atmosphere of 5% 
CO2.  Cells were fed every 2-3 days and subcultured once they reached 70-80% 
confluence in order to prevent the loss of differentiation potential. For this routine, 
subculturing cells were first rinsed with 1x phosphate buffered saline (PBS) (0.137M 
NaCl, 2.7mM potassium chloride (KCl), 1.4mM potassium hydrogen phosphate 
(KH2PO4), 0.01M sodium hydrogenophosphate (Na2HPO4)) and then incubated with 1 
volume of trypsin-EDTA for 5 min at 37 °C. Trypsin activity was inhibited by the 
addition of 1 volume of complete growth medium and the final volume was centrifuged 
at 115 xg for 5 minutes at room temperature. An appropriate aliquot of the cell 
suspension was added to new culture flasks. Cells were used between passages 4 and 
21. 
In order to answer our question, H9c2 cells were seeded and cultured for 24 hours 
in high-serum that promoted proliferation. After this time, the medium was changed to 
DMEM serum and phenol-red free media supplemented with L-glutamine (4mM), 
glucose (250mM), sodium bicarbonate (17.8mM), taurine (60mM), creatine (20mM), L- 
carnitine (1mM), insulin (1mg/ml)-transferrin (0.55mg/ml )-sodium selenite (0.5μg/ml) 
(ITS), BSA 10% and hydrocortisone (50μg/ml) (Table 1). Cells were cultured for 3 
more days to allow the adaptation to new conditions.  
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Experiments were thus conducted in two experimental groups: (a) 
undifferentiated myoblasts in 10% serum (b) differentiated muscle cells in serum-free 
medium. 
For Western Blot assays, cells were seeded in 150mm bottom diameter
 
dishes 
with the density of 5,000 cells/cm
2
 for the 10% serum condition and 8,000 cells/cm
2
 for 
serum-free condition. 
 
 
Medium composition 
Serum-free 10% Serum 
DMEM BASE D5030 (Sigma, St. Louis, 
MO, USA) 
 
Supplemented with: 
 
L-glutamine (4mM), glucose (250mM),  
sodium bicarbonate (17.8mM), taurine 
(60mM), creatine (20mM), L- carnitine 
(1mM),  insulin (1mg/ml)-transferrin 
(0.55 mg/ml )-sodium selenite (0.5 μg/ml) 
(ITS), 10% of BSA and hydrocortisone 
(50μg/ml). 
DMEM D5648 (Sigma, St. Louis, 
MO, USA) 
 
Supplemented with: 
 
 1.5 g/ml of sodium bicarbonate and 
10% of FBS 
Table 1 - Differences between the media composition used in this work. 
Figure 9 - Experimental design of cell culture and collection. Cells were seeded in high serum medium 
and after 24 hours, corresponding 0 hours time point, the medium was replaced by a serum-free modified 
medium. After that, cells were maintained in the same medium during 72 hours, being collected for 
western blot after this time in culture. 
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In order to answer our second objective, H9c2 cells were seeded and cultured for 
24 hours in high-serum media. After this time the medium was changed to serum-free 
medium and cells were cultured for 3 more days to allow the adaptation to new 
conditions. In the third day, cells were treated as desired and experiments were 
performed in five experimental conditions: (a) Control BSA, (b) Control PA, (c) 
Estradiol plus PA, (d) Enterodiol plus PA, (e) coumestrol plus PA. 
 
 
 
 
 
 
 
 
 
 
 
For the present thesis, the cytotoxic effect of PA on H9c2 cells was evaluated to 
determine the exposure time and concentration of PA to use in the following 
experiments. The cell line was cultured according as described above and was seeded 
with the density of 8,000 cells/cm
2
 in 48 well-plates. The cell treatment was performed 
Figure 10 - Experimental design of cell culture and treatment.  Cells were seeded in high serum medium 
and after 24 hours, corresponding to time 0 hours, the medium was replaced by serum-free medium. 
After that, cells were maintained in the same medium during 72 hours, being (A) treated with PA (up 
500µM) during 24h, 48 and 72h in order to evaluate the cytotoxicity by SRB assay; (B) treated with PEs 
(coumestrol, enterodiol) and 17β-estradiol (up to 10µM) during 27h and 30h in order to evaluate the 
cytotoxicity by SRB assay; (C) treated with PEs during 3h or 6h (up to 10µM) and after with PA 
(50µM) during 24h and cell mass was evaluate by SRB assay; (D) treated with 50μM of PA 3h after 
treatment with PEs (1µM ) and 17β-estradiol (100nM) and was maintained for 24h. Several parameters 
were evaluated, including mitochondrial membrane potential by flow cytometer and protein content by 
Western Blot. 
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with different PA concentrations (0, 50, 100, 250 and 500μM) for 24, 48 and 72h. The 
cytotoxic effect of PA on H9c2 cells was assessed by the SRB assay. Control with BSA, 
the vehicle for palmitic acid was also performed. 
In order to evaluate PEs cytotoxicity, H9c2 cells were treated with PEs (enterodiol 
and coumestrol) and 17β-estradiol with concentrations of 0.1μM, 1μM and 10μM 
during 27 hours or 30 hours of incubation, the total time that cardiomyoblasts were 
incubated with PEs (3 and 6 hours of pre-incubation plus 24 hours with PA). Control 
with 0.1% of DMSO (the vehicle for PEs) was also used. After treatment, H9c2 cell 
density was assessed by the SRB assay. 
 
3.4. Samples  
3.4.1. Total Protein isolation 
In order to obtain cellular extracts, H9c2 cells were harvested by trypsinization 
and washed once with 1x PBS with two centrifugation steps performed at 1,000 xg for 5 
minutes at 4 °C, cells were lysed in cell lysis buffer (Cell Signaling, Danvers, MA, 
USA) supplemented with 1 mM PMSF. The cell suspension was then rapidly frozen and 
kept at -80 °C until used. For protein analysis by western blot, the protein contents were 
determined by the Bradford method, using BSA as a protein standard.  
  
3.5. Protein quantification  
3.5.1. Bradford Assay 
The Bradford method is based on the binding of Coomassie Brilliant Blue G-250 
dye to proteins, being converted to a stable unprotonated blue form with maximum 
absorbance of the 595 nm (Bradford, 1976). Compto and Jones (Compton and Jones, 
1985) demonstrated that this dye binds primarily to basic (especially arginine) and 
aromatic amino acid residues. 
The Bradford Reagent 2x was prepared by adding 0.02% (w/v) Brilliant Blue G, 
5% (v/v) methanol and 8.5% (w/v) phosphoric Acid. BSA was used as a standard with 
protein solutions ranging from 0.125mg/ml to 2mg/ml. The reaction was initiated by 
adding 100 μL of working reagent diluted 1:2 in ultrapure water to 5μL of sample 
diluted 1:100 in ultrapure water and collection buffer, in a 96 microplate (Table 2). 
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After 20 minutes incubation at room temperature, the absorbance of the wells was read 
in a VICTOR X3 plate reader (Perkin Elmer Inc.) at 595 nm. Standards and unknown 
samples were performed in triplicates. 
 
 
Table 2 - Quantification table for Bradford assay with standards and samples preparation 
 
Tube # 
[Standard] 
(mg/ml) 
Standard 
Volume (µl) 
Collecting 
buffer (µl) 
dH2O 
(µL) 
[Protein]final 
(µg/ml) 
1 2 5 10 485 20 
2 1 5 10 485 10 
3 0.5 5 10 485 5 
4 0.25 5 10 485 2.5 
5 0.125 5 10 485 1.25 
6 (blank) ----- ---- 10 490 0 
Sample (µl) 
Unknown ----- 5 5 490 ----- 
 
 
3.6. Protein analysis by Western Blot 
After protein quantification, samples were prepared in 6x concentrated Laemmli 
Buffer (5µL of sample to 1µL of Laemmli buffer 6x) to achieve a working 
concentration of 1.25 μg/mL. When the Laemmli buffer contains detergent (SDS in the 
present case), all of the proteins obtained a uniform negative charge that provides a 
separation according to their molecular size (Gallagher, 2012).  
In order to denaturate protein, samples were heated at 95 °C for 5 minutes, 
allowing the loss of quaternary, tertiary and secondary protein structure. Subsequently 
equivalent amounts of proteins (10 to 25 μg) were separated by electrophoresis on 10% 
or 14% SDS-polyacrylamide gels (SDS-PAGE), depending on the molecular size of the 
proteins of interest, allowing for a better separation resolution. Acrylamide and bis-
acrylamide are two compounds that after polymerization allow the formation of 
polyacrylamide gels. The polymerization was initiated by the addition of ammonium 
persulfate (APS) and catalyzed by TEMED. Separation was carried out at room 
temperature and until the front of the run reached the bottom end of the gel. When 
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protein separation was complete, proteins were electrophoretically transferred to a 
polyvinylidene difluoride (PVDF) (Millipore, Billerica, MA, USA) membrane pre-
activated (5 sec in 100% methanol followed by 15 min in 25mM Tris, 190mM glycine 
and 20% methanol). For this purpose, gels were placed in a 'transfer sandwich' (filter 
paper-gel-membrane-filter paper) and protein transfer was performed at a constant 
voltage (100V) during 90 min at 4 °C. 
Once protein transfer was complete, membranes were stained with Ponceau 
reagent before blocking to confirm equal protein loading in each lane (Colella et al., 
2012; Gilda and Gomes, 2013). Afterwards, membranes were incubated with blocking 
solution, 10 % non-fat dry milk or 5 % BSA in Tris-buffered saline Tween-20 (TBS-T) 
(154mM NaCl, 50mM Tris pH 8.0 HCl) and 0.1% Tween-20, depending of the protein 
of interest, overnight at 4 °C with agitation to block non-specific binding. Membranes 
were then incubated with a primary antibody directed against the respective protein 
overnight at 4 °C (Table 3). Primary antibodies were prepared in 1% non-fat dry milk 
or 1% BSA solution in TBS-T supplemented with sodium azide to a final volume of 5 
ml.  
Membranes were further washed with TBS-T and incubated with alkaline 
phosphatase conjugated secondary antibodies (1:2,500 dilution) for 1 hour at room 
temperature under continuous stirring. Finally, membranes were washed again and 
incubated with the Enhanced Chemi-Fluorescence (ECF) detection system (from 
Amersham, Little Chalfont, Buckinghamshire, United Kingdom) and read with a Versa 
Doc imaging system (Bio-Rad). The ECF substrate is dephosphorylated by alkaline 
phosphates that are present in secondary antibody, leading to the formation of a 
fluorescent product which emits at 540 to 560 nm when excited. Densities of each band 
were calculated with Quantity One Software (Bio-Rad).  
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Table 3 - List of primary antibodies used in Western Blot protein analysis. 
 
 
3.7. Cell density evaluation by Sulforhodamine B (SRB) assay 
Sulforhodamine B is a bright-pink aminoxanthene dye with two sulfonic groups 
that bind to basic amino-acid residues under mild acidic conditions (Vichai and 
Kirtikara, 2006). This colorimetric method is based on measurement of cellular protein 
content and depends on the ability of SRB to bind to protein components of cells that 
have been fixed by methanol (Vichai and Kirtikara, 2006). 
This assay was performed in order to evaluate the cytotoxic effects of PA, the 
selected PEs and the protective effects of PEs against PA-induced lipotoxicity. After 
treatment, cells were washed in PBS and fixed in ice-cold methanol supplemented with 
1% acetic acid for at least one hour at -20 °C and allowed to dry. After that, 0.05% SRB 
dissolved in 1% of acetic acid was added to each well and incubated for 1h at 37 °C. 
The unbound dye was removed with 1% acetic acid solution and allowed to dry. The 
dye bound to cell protein was solubilized in 10mM Tris pH 10 solution and the optical 
density of the solution was determined at 530 nm in a Victor X3 plate reader (Perkin 
Elmer Waltham, USA). 
 
3.8. Evaluation of mitochondrial membrane electric potential 
The mitochondrial membrane electric potential (ΔΨm) was evaluated using 
tetramethylrhodamine methyl ester (TMRM) probe by distinct methods, flow cytometer 
and microscopy. This probe is a lipophilic cation that accumulates in polarized 
mitochondria according to their Δψm value because of their charge and solubility in both 
Primary 
Antibody 
Molecular 
weight 
Dilution Host 
specie 
Company Catalog 
Number 
GATA4 54kDa 1:1,000 Rabbit abcam ab134057 
Troponin T 40kDa 1:500 Rabbit Cell Signaling 5593 
MLC 2v 19kDa 1:1,000 Mouse Synaptic 
Systems 
310.111 
Beclin-1 60kDa 1:2,000 Rabbit Cell Signaling 3595 
p62 62kDa 1:1,000 Rabbit MBL PM045 
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the inner mitochondrial membrane and matrix space (Scaduto and Grotyohann, 1999). 
The extent of its accumulation, as measured by intensity of cellular fluorescence, is 
proportional to cellular Δψm (Wlodkowic et al., 2009). The decreased intensity of  
TMRM fluorescence is associated to cells with collapsed mitochondrial transmembrane 
potential (Wlodkowic et al., 2009). 
 
3.8.1. Flow cytometer  
On the day of the assay, treated cells were harvested by trypsin treatment and 
ressuspended in the following buffer: 120mM NaCl, 3.5mM KCl, 0.4mM KH2PO4, 
20mM HEPES, 5mM sodium bicarbonate, 1.2mM sodium sulfate (NaSO4), 10mM 
sodium pyruvate at pH 7.4 supplemented with 1.2mM magnesium chloride (MgCl2), 
1.3mM calcium chloride (CaCl2). Incubation with 100nM TMRM (Invitrogen, 
Molecular Probes) for 30 min at 37 °C was performed. A sample of non-labeled cells 
was also analyzed in order to calibrate the system, taking cell self-fluorescence into 
account. Cells (10,000 cells) were analyzed on a FACSCalibur flow cytometer (BD 
Biosciences, San Jose, California, USA), using the FL2 filter sets. During preliminary 
tests, all cell groups without TMRM were analyzed to ascertain the sensitivity, 
reliability and best analysis to perform. Data was analyzed using BD CellQuest Pro 
software package. 
 
3.9. Statistics analysis 
 Data analysis was performed by using GraphPad Prism 6.0 program (GraphPad 
Software, Inc.) and data were expressed as mean ± SEM for the number of experiments 
indicated in the legends of the figures. For statistical analysis of two means, including 
for comparison of control groups (10% Serum) and serum-free medium, the Student’s t 
test was performed. Multiple comparisons were performed using one-way analysis of 
variance (ANOVA) or two-way ANOVA, depending on the variables under study. For 
one- and two-way ANOVA, corrections for multiple comparisons were made using 
Bonferroni post-hoc test. Significance was accepted with p value < 0.05. 
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4. RESULTS 
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4.1. Characterization of H9c2 cardiomyoblasts 
4.1.1. H9c2 cells can differentiate into cardiomyocytes in absence of  
  serum  
In this chapter, we aim to characterize the H9c2 differentiation process when 
cultured in serum-free medium. During the differentiation process, alterations are 
observed in H9c2 cells, including myoblasts fusion to form multinucleated and larger 
cells, reduced proliferation, and increased content in specific markers for adult 
cardiomyocytes (Menard et al., 1999). In this study, cells were maintained in serum-free 
medium in order to avoid interference with serum’s estrogens, as described before. 
Thus, we investigated whether serum-free medium-driven cell differentiation leads to 
increase of specific markers for adult cardiac cells. In this regard, GATA4, Mlc2v and 
Troponin T were selected because they are recognized of markers of cardiac 
differentiation (Molkentin et al., 1997; Ng et al., 2010; York et al., 2007). GATA4 is a 
cardiac-specific marker that is implicated in heart development (Molkentin et al., 1997).  
In the contractile system, cardiac troponin T has a fundamental role, and is also present 
in a confined stage of fetal skeletal muscle development (Swiderski and Solursh, 1990). 
The degradation of cardiac troponin T is also associated with dysfunction in the 
contractile structure during cardiac pathologies (Beatty et al., 2013). Although no 
differences were observed between cells grown in 10% serum and serum-free medium, 
it is possible to observe that all cardiac markers were similar in both tested groups 
(Figure 11).  
Additionally, is important refer that the results were normalized to Ponceau 
labeling. This experimental strategy was preferred over the use of housekeeping 
proteins because they can be affected by the differentiation process, since that H9c2 
cells morphology alters in this condition. 
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Figure 11 - Western Blot analysis of specific cardiac markers in cells grown in 10% serum and serum-
free medium. (A) GATA4 (B) Mlc2v (C) Troponin T protein content, three recognized cardiac m 
markers.  The images and quantification are representative of 4 separate experiments from independent 
cell cultures and bars show mean±SEM. Control loading was performed by using Ponceau labeling. 
Protein levels were normalized to Ponceau. 
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4.1.2. Autophagy pathways is activated when H9c2 cells were cultured in  
  serum-free media 
Taking into account that serum starvation can lead to activation of autophagy 
pathways, the next question was how serum absence affects these processes of quality 
control in cells. Moreover, alterations in autophagy can occur during cell differentiation, 
in which morphological and biochemical transformation are required.  In this regard, 
several autophagy markers were evaluated through Western Blot in H9c2 cells. First, we 
evaluated Beclin-1 protein content, after culture of H9c2 cells during 72h in serum-free 
medium. This protein is required for the promotion of autophagossome formation in 
cytoplasm, initiating macroautophagy (Levine and Kroemer, 2008). The results showed 
an increase of Beclin-1 protein content in myoblasts cultured in medium without serum, 
when compared to control (10% of serum) (Figure 12).  
 
 
 
 
 
 
 
 
Figure 12 - Alterations in autophagy pathways during H9c2 myoblast differentiation. (A) Beclin-1, 
associated with autophagosome formation, was evaluated by Western Blot. Beclin-1 protein content in 
H9c2 cells was increased when compared to 10% serum control. (B) The p62 protein content was 
decreased in cells cultured in serum free medium, when compared to 10% of serum control. The images 
and quantification are representative of 4 separate experiments (for Beclin-1) and 3 separate experiments 
(for p62) from independent cell cultures and bars show mean ±SEM (*p<0.05 and **p<0.01, two-tailed t-
students test). Control loading was performed by using Ponceau labeling. Protein levels were normalized 
to Ponceau. 
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Altogether, cell culture in serum-free medium results in an increase of Beclin-1. 
These results suggest that autophagy signaling may be activated when H9c2 cells are 
cultured in serum-free medium. 
Moreover, to confirm that autophagy signaling was activated, autophagy flux was 
evaluated by analysis of p62 protein content by western blot. The p62 protein is 
involved in the recognition of toxic cellular waste by interaction with polyubiquitinated 
cargo (Komatsu and Ichimura, 2010). Additionally, p62 interacts with LC3 during 
autophagosome formation (Mizushima and Komatsu, 2011). Taking into account its 
role in autophagy, p62 is considered a marker for autophagy flux in cells (Komatsu and 
Ichimura, 2010; Komatsu et al., 2012). Thus, suppression in autophagy leads to an 
accumulation of p62 (Komatsu and Ichimura, 2010). As can be seen in Figure 12, a 
significant decrease in levels of p62 protein content was observed in cells cultured in 
serum-free medium in comparison with control group (10% of serum). 
In summary, the presence of main autophagy markers as well as the decreased 
levels of p62, suggest an augmented autophagy flux in H9c2 cells cultured in serum-
free medium.  
 
4.2. Protection provided by phytoestrogens against lipotoxicity  
4.2.1. Palmitic Acid decrease cell proliferation of cardiomyoblasts 
The cytotoxicity associated with PA was assessed on H9c2 cardiomyoblasts in the 
concentration range of 50 - 500µM using SRB assay, after 24h, 48h and 72h. Cells were 
exposed to palmitic acid-BSA conjugate or to BSA only.  
Figure 13A shows cell density in relation to time zero, which is the time that the 
treatment begins, while Figure 13B shows cell density in comparison to control with 
vehicle, BSA.  
The results in both graphs show decreased cell density of cardiomyoblasts in a 
dose-dependent manner for each incubation time. The toxicity of palmitic acid was 
statistically significant starting from 50µM PA in all incubation time points (24h, 48h 
and 72h).  However, for the higher PA concentrations (from 100µM) cell mass did not 
change. Based on toxicity assays, 50µM concentration of PA during 24 hours was 
chosen for further experiments, aimed at measuring the protection afforded by PEs. 
Taking into account the literature, this concentration of palmitic acid is physiologically 
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appropriate. Total plasma FAs can be as high as 1mM or even higher under some 
pathologies but including obesity or metabolic syndrome (Belfort et al., 2005). 
Figure 13 - Palmitic acid (PA) decreases cell proliferation of H9c2 cardiomyoblasts (A) The % of cell 
density in relation to time zero and (B) the % of cell density in comparison to control BSA only. Data 
represent mean ±SEM from 6 independent experiments and were analyzed by two-way ANOVA 
following Bonferroni’s multiple comparison test, using GraphPad Prism software. *p<0.05 and 
****p<0.0001 when compared to control with BSA. 
 
4.2.2. Phytoestrogens tested showed a reduced toxicity in H9c2   
  cardiomyoblasts 
The evaluation of cytotoxicity of PEs in H9c2 cells was assessed by the SRB 
assay, after treatment with 0.1, 1 and 10µM during 27 and 30 hours. These two times 
A 
B 
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correspond to, 3 and 6 hours of pre-incubation, respectively. This evaluation is 
important in order to ensure that doses used are not toxic to H9c2 cells. The obtained 
results demonstrate that all compounds in study do not have toxicity for different 
concentrations during 3 or 6 hours of pre-incubation (Figure 14). Since no statistically 
differences were observed, coumestrol and enterodiol showed little or no cytotoxicity. 
Estradiol also did no present any toxicity in the time points and concentrations tested 
(Figure 15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 - Cytotoxicity of PEs (enterodiol and coumestrol) in H9c2 cardiomyoblasts during 27 and 30 
hours with different concentrations (up to 10µM). Data represent mean ±SEM from 6 independent 
experiments and were analyzed by two-way ANOVA, using the GraphPad Prism program. 
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4.2.3. The effect of phytoestrogens against palmitic acid toxicity 
4.2.3.1.  Cell Density Evaluation  
Based on the previous results, we pre-treated the cells with different 
concentrations of coumestrol and enterodiol and 17β-estradiol during 3 and 6 hours and 
then incubated cells with PA (50µM) for 24 hours. By measuring cell mass with the 
SRB dye method, the protective effect of PEs and 17β-estradiol was evaluated against 
PA lipotoxicity (Figure 16). The results showed a significant decrease in H9c2 cell 
density after 24 hours of treatment with 50µM PA, compared to control BSA, which is 
consistent with previous results (Figure 13B). Regarding the protective effects of 17β-
estradiol against PA, no statistically significant differences were observed in 
comparison with 50µM of PA, for both pre-incubation times. Relatively to coumestrol 
and enterodiol no protective effect on PA-induced loss of cell mass was observed, with 
results being similar for both incubation times. Despite the lack of protective effects, 
concentrations of 0.1µM and 1µM were chosen for 17β-estradiol and PEs, respectively. 
The pre-treatment time selected for further experiments was set for 3 hours. 
 
Figure 15 - Cytotoxicity of 17β-estradiol in H9c2 cardiomyoblasts during 27 and 30 hours with 
different concentrations (up to 10µM). Data represent mean ±SEM from 6 independent experiments and 
were analyzed by two-way ANOVA, using the GraphPad Prism program. 
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Figure 16 - Cell density evaluation. H9c2 cells were treated with different concentrations of 17β-
estradiol and PEs (0.1µM, 1μM and 10μM) while treatment with 50μM of PA was performed 3 hours 
after treatment with PEs and was maintained for 24h. Control with 0.83mM of BSA without PA was 
also performed. Data are expressed as mean ± SEM of 3 independent experiments and were analyzed 
by one-way ANOVA following Bonferroni’s multiple comparison test, using the GraphPad Prism 
program; * p<0.05; **p<0.01; ***p<0.001; ****p<0.0001when compared to PA. 
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4.2.3.2. The evaluation of mitochondrial membrane electric potential 
In order to assess the possible impact of PA on mitochondrial function and also 
the protective effects of PEs against PA, alterations in ΔΨm were evaluated in all 
experimental groups through flow cytometry using the fluorimetric probe TMRM.  
For this purpose and based on previous results, H9c2 cells were treated with 17β-
estradiol (100nM), enterodiol (1µM) and coumestrol (1µM) during 3 hours and 
incubated with PA (50µM) for 24 hours more. No alterations on TMRM fluorescence 
were found based on flow cytometer results. PA-treated cells appeared to have lower 
TMRM fluorescence, suggesting a decrease in Δψm when compared with control (BSA-
treated cells), although the difference was not significant. However, when cells were 
incubated with coumestrol plus PA, increased TMRM fluorescence was measured 
which may result from increased mitochondria transmembrane electric potential when 
comparing to cells treated with PA alone (Figure 17). 
 
 
 
 
 
 
 
 
 
 
 
Figure 17 – TMRM fluorescence in H9c2 cells treated with 17β-estradiol (0.1µM), enterodiol (1µM) and 
coumestrol (1µM) during 3 hours and with 50μM of PA for 24 hours more. Control with 0.83mM of BSA 
without PA was also performed. Mitochondrial membrane potential alterations were evaluated using 
TMRM probe and analyzed through flow cytometry Data are means of 3 independent experiments, plus 
SEM. * p< 0.05 vs. PA (50µM). 
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4.2.3.3. Autophagy markers  
Finally, we intended to demonstrate if cell treatment with PA leads to alteration in 
autophagy markers and if the incubation with PEs was able to reverse those alterations. 
In this regard, protein content of autophagy markers, Beclin-1 and p62, was evaluated 
by Western Blot in all H9c2 cell groups. After 72 hours in serum-free medium culture, 
cells were treated with PEs during 3 hours and after this time were incubated with 
50µM of PA and in the end were collect and western blot was performed. 
Alterations of Beclin-1 protein content in all cell groups was not statistically 
significant; however the results showed a slight decrease in protein content in cells 
treated with PA when compared with control BSA as well as a small increase in cells 
treated with PEs and 17β-estradiol in comparison to cell group treated with PA (Figure 
18A). The p62 protein content was also assessed allowing exploring the autophagy flux 
in all cell groups. As can be seen in figure 18B no differences existed in p62 protein 
content between all cell groups, suggesting that autophagy flux is not altered with cell 
treatment, although a larger number of samples must be tested. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 51 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18- Alterations in Beclin-1 and p62 during H9c2 myoblasts treatment with PE/PA. (A) 
Beclin-1, total protein was evaluated by Western Blot (B) p62, measured by Western Blot and no 
differences was observed between all cell groups. Protein levels were normalized to Ponceau 
labeling (N=2), bars show mean ±SEM. 
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H9c2 cardiomyoblasts are a recognized in vitro cellular model for cardiac cells 
due their morphological features and electrophysiological characteristics (Menard et al., 
1999). In a wide variety of experimental designs, this cell line is usually used in an 
undifferentiated state (Sardao et al., 2007, 2009a, b).  Nevertheless, H9c2 myoblasts can 
fuse and differentiate into skeletal muscle cells when cultured in a low-serum medium. 
Likewise, a cardiac-phenotype can be obtained after differentiation in a low serum and 
supplemented with all-trans RA (Menard et al., 1999). Cardiac specific markers, 
including expression, troponin T, MLC2v and phosphorylated troponin I have been 
demonstrated to occur after cardiac differentiation (Branco et al., 2011; Pereira et al., 
2011). This differentiation capacity of H9c2 myoblasts allows using this model for 
toxicology studies, since the use of undifferentiated H9c2 cells may not be the best 
approach to use as a cardiac cell surrogate. Additionally, the adult heart tissue is 
composed by differentiated cardiomyocytes and therefore toxicological studies can have 
different effects depending on the developmental state of the biological model used 
(Branco et al., 2011; Branco et al., 2012; Branco et al., 2013). 
Taking into account all the considerations previously mentioned, and also gearing 
towards our main study, a question is created: does cells cultured in the absence of 
serum differentiate in cardiac muscle cells? In this regard, one of the objectives in the 
first part of the present thesis was to characterize H9c2 cardiomyoblasts in the absence 
of serum in culture medium, since FBS, contains hormonal factors and other growth 
factors which stimulate cell proliferation. So, a cell culture system lacking hormone-
surrogates must be developed. 
We observed by Western Blot that cells cultured in the absence of serum have the 
same protein content in GATA4, MLC2v and Troponin T (Figure 11), markers for 
cardiac differentiation, when compared with cell cultured in 10% of serum. The 
transcription factor GATA4 is considered one of the early cardiac genes required for the 
initiation of cardiac differentiation  (Yilbas et al., 2014) being involved in cardiogenesis 
during the development (Morin et al., 2000; Turbendian et al., 2013; Yilbas et al., 
2014). Therefore, the results presented in Figure 11(A) are in agreement with these 
reports, since that cells cultured in 10% of serum are derived from embryonic rat heart 
(Kimes and Brandt, 1976) and thus can express this transcription factor.  
The cardiac troponin T although it is a widely used cardiac marker, it can also be 
present in a confined stage of fetal skeletal muscle development (Swiderski and Solursh, 
1990). Moreover, these results are in agreement with the fact that differentiation 
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protocols produce heterogeneous populations (Menard et al., 1999).  Furthermore is 
important to mention that the initial cell confluence and how cells were maintained in 
terms of confluence influence the differentiation process and the expression of cardiac 
markers in a specific undifferentiated population is very dependent of these particular 
features. Moreover, the use of the present cell culture model raises the question whether 
nutrient deprivation and serum withdrawal can activate autophagy signaling. Several 
reports revealed that autophagy can be stimulated during starvation or even growth 
factor nutrient deprivation (Ichimura and Komatsu, 2010; Levine and Yuan, 2005).  
Concerning the results presented in Figure 12(A), in general, cells cultured in the  
absence of serum showed an increase in proteins involved in the autophagic pathway, 
such as Beclin-1, which has an important role in the initiation of autophagy allowing 
vesicle nucleation (Choi et al., 2013). This suggests that autophagy pathways are 
stimulated, although more data and end-points are necessary to investigate this. One 
important autophagic marker is p62, a selective substrate for autophagy because it is 
incorporated in the autophagosome by interaction with LC3 (Komatsu et al., 2012). 
During autophagic stimulation, p62 decreases, the opposite occurring when autophagy 
is suppressed. In this context, the data presented in Figure 12(B) demonstrated that cells 
cultured in serum-free medium showed decreased p62 protein content, indicating 
increased autophagic flux. The conjugation of both experiments is a good experimental 
approach because the evaluation of p62 by itself is not sufficient to estimate autophagic 
flux, since the expression of this protein can be changed independently of autophagy 
(Kuusisto et al., 2001). Likewise, the measurement of autophagic markers, such as 
Beclin-1, is also not sufficient to confirm the stimulation of autophagy pathways. 
Overall, the results suggest activation of autophagy pathway when H9c2 cells are 
cultured in serum-free medium.  
Autophagy has fundamental roles in physiology and pathology, including adaptive 
responses due to starvation, even growth factors deprivation, cellular quality control, 
aging and others (Choi et al., 2013; Klionsky, 2000). Furthermore, autophagy can be 
required for cellular differentiation, which is associated with alteration on cell 
morphology, signaling pathways and function (McMillan and Quadrilatero, 2014; 
Mizushima and Levine, 2010). During differentiation, alterations in autophagy occur in 
several types of cells, including myoblasts (McMillan and Quadrilatero, 2014; Pantovic 
et al., 2013; Zeng and Zhou, 2008; Zhuang et al., 2011). 
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During myoblast differentiation and mature myotube formation, degradative 
processes are important. However, myoblasts differentiation involves a significant 
remodeling which requires the induction of autophagy (McMillan and Quadrilatero, 
2014). Regarding these facts, a recent study using mouse C2C12 skeletal myoblasts 
demonstrated that during myoblast differentiation an alteration in autophagy markers 
occur, showing increased Beclin-1 and decreased p62 (McMillan and Quadrilatero, 
2014). These findings are consistent with results obtained in the present thesis, 
concerning the differentiation of H9c2 cells in serum-free medium. Therefore, our 
explanation for these observations relates to the fact that the stimulation of autophagy 
due to an external signal, such as absence of cell growth of the cells, promotes 
differentiation and remodeling, facilitating the elimination of pre-existing structures and 
proteins (McMillan and Quadrilatero, 2014). Additionally, autophagy activation may 
act as a mechanism of cell survival, allowing the cell to reuse free fatty acids and amino 
acids generated by degradation of membrane lipids and proteins by the autolysosome. 
This mechanism promotes the maintenance of mitochondrial ATP energy generation 
and protein synthesis for cell survival (Levine and Yuan, 2005). Altogether, our 
findings, together with literature reports, allow us to confirm that autophagy activation 
is important in the context of cell survival or even cell differentiation, being related to 
its ability to sustain life during growth nutrients deprivation. Notwithstanding, it is 
crucial a controlled regulation of autophagy during myoblast differentiation, since 
excessive autophagy can be harmful for cells (Iovino et al., 2012).  
Despite the benefic effects of PEs in health, and potential role in menopause, 
several questions are still unanswered, including their toxicity or the real extent of their 
benefic effects.  
The role of PEs in the protection against cardiac lipotoxicity has not yet been 
explored, specially focusing on the inhibition of mitochondrial dysfunction through 
fatty acid overload. In this sense, we investigated the protective effects of PEs against 
lipotoxicity in H9c2 cells, using PA as a lipotoxicity-inducing agent. It has been 
demonstrated that cell treatment with saturated FA, including PA, triggers apoptosis in 
cell cultures (Listenberger et al., 2003). Also PA toxicity occurs  via de novo ceramide 
formation and induces damages on contractile elements and cytoskeleton in adult rat 
cardiomyocytes (Dyntar et al., 2001). Therefore, this is a relevant model since during 
menopause women have elevated serum FAs and increased risk of CVD. The initial 
experimental approach regarding the second part of present study was to evaluate only 
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the effect of PA on the proliferation of H9c2 cells and afterwards the assessment of PEs 
alone on H9c2 cell mass. 
Palmitic acid is cytotoxic for the cell line in study in a dose - and time-dependent 
manner but with a maximal effect obtained for 100μM. A recent study also evaluated 
the effect of palmitate in C2C12 myoblasts and myotubes, demonstrating that palmitate 
decreased the viability of the cells in study in a dose-dependent manner with results 
being significant starting from 0.05mM PA in myoblasts (Patkova et al., 2014). The 
same effect was observed with neuronal stem cells, where their viability is suppressed 
when cells are treated with PA (Wang et al., 2014). Altogether, our data and previous 
reports show that PA-induced toxicity is useful for clarifying the role of FAs, since that 
PA has important impact on proliferation of cardiomyoblast in vitro.  
Although there are studies demonstrating positive effects of PEs treatment in 
several diseases related with menopause, it is important to take into account that its 
excessive consumption can trigger harmful effects on health. Not to mention that not all 
PEs provided protection or even increased women’s quality life during menopause. For 
this purpose, is critical to perform the screening of PEs in our experimental model in 
order to test the toxicity of the compounds in study (coumestrol and enterodiol) and also 
to roughly estimate safe concentrations. Thus, assessment of PEs toxicity on myoblast 
proliferation was also performed with different concentrations and two different 
incubation times. The results presented in Figure 14 showed that no toxicity occurs with 
any of the concentrations tested. As well as, no differences was observed between both 
time points (27 and 30 hours). These results are in agreement with several studies 
showing that some PEs, including genistein may have beneficial effect in the heart (Fan 
et al., 2013) and resveratrol (Zhao et al., 2008). Despite the reduced toxicity in this cell 
model, or in the whole tissue it is crucial to take into account that PEs, including 
genistein, coumestrol and resveratrol can exert genotoxic effects in several in vitro 
models (Stopper et al., 2005). 
As stated before, PEs are recognized to be cardioprotective. Thus, one of the main 
goals of the present thesis was to evaluate the protective effects of coumestrol and 
enterodiol against PA-induced lipotoxicity. Considering the results present in Figure 16, 
we can conclude that at least by using this method, there was no evident protection from 
PEs against PA lipotoxicity. A non-statistically tendency for protection observed for 
1µM of coumestrol and enterodiol during 3 hours of pre-incubation, may suggest that 
extra work may be needed in this regard. 17β-estradiol did not show any significant 
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effect, this despite the results showing a small, non-significant protection for the lowest 
concentration. 
The charge imbalance that results from the generation of an electrochemical 
gradient across the inner mitochondrial membrane forms the basis of the Δψm (Kroemer 
et al., 2007). Therefore, the maintenance of the proton gradient is crucial for the 
survival the cell, since it leads to the synthesis of ATP and maintains oxidative 
phosphorylation (Ly et al., 2003). In this context, Δψm was evaluated in all cell groups 
in study. Our data demonstrated that PA caused a small ΔΨm decrease, which was not 
significant, most likely because of the low number of replicates. In the other hand, pre-
treatment with coumestrol during 3 hours increased Δψm in the presence of PA, although 
the mechanism is not known.  
 Recently, Cai and colleagues (Cai et al., 2014) reported evidences of autophagy 
activation induced by PA in several cell lines, including hepatocytes. In this regard, we 
assessed autophagy markers in our cell line model, and investigated whether PEs may 
be protective in this context. However, the results no alterations in autophagy markers, 
suggesting unchanged autophagy fluxes. Taken together, the results show modest 
protection by the PEs used, with coumestrol showing the more promising effects. One 
important issue concern the cell model used. The present work should be replicated in 
primary cardiomyocytes, a more closely related model and in which the PEs studied 
may present more robust effects. 
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6. CONCLUSION 
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Several complications during menopause exist, namely lipotoxicity associated 
with the accumulation of FFA in the cell, contributing to the risk of CVD. Since 
estradiol has a cardioprotective effect the main hypothesis of the present study was that 
PEs protect cardiac tissue against cardiac lipotoxicity induced by FFA (Oliveira et al., 
2012). The H9c2 cell line, a model for cardiac cells was used in the present study. 
Notwithstanding, the problems raised due to the serum used, led us to develop a new 
cell culture approach which may have disturbed the results obtained. 
Since during menopause women have elevated serum fatty acids and increased 
risk for CVD, it is possible that some PEs can be used to ameliorate the cardiovascular 
performance of menopausal women, without further side effects to health. Inclusion of 
PEs in specific foods or dairy products can be a possible innovative strategy in the 
future for therapeutic of problems during menopause. Thus, this is clearly of relevance 
for geriatric studies and commercially important for the food industry. 
Nevertheless the present results were inconclusive since no protection was 
observed from the used PEs in PA-induced lipotoxicity. A better cell model or treatment 
protocols may help confirming our hypothesis in the future. 
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7. FUTURE EXPERIMENTS 
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Although PEs are widely studied in the context of several diseases, their 
effectiveness and safety is still under debate. This is particularly important in the 
context of cardiovascular diseases. In this regard, and taking into account the data here 
presented, further experiments in the same or alternative cell models can be performed, 
namely: 
 
   Evaluation of apoptosis (intrinsic pathway) by measuring caspases 3 and 
9-like activity by a colorimetric assay. The objective is to investigate the anti-
apoptotic activity of PEs studied here against PA toxicity. Also, this allows 
providing the underlying molecular mechanisms of PEs on PA-induced 
cardiomyocytes apoptosis, since we used here a technique (SRB labelling) that 
does not distinguish between cell death or arrest of cell cycle. 
  Detection of intracellular oxidative stress by flow cytometer and 
fluorescence microscopy using the probes 5-(and-6)-chloromethyl-2',7'-
dichlorodihydrofluorescein diacetate (CM-H2DCFDA) or MitoSox Red in order 
to assess the potential antioxidant effect of PEs per se and against the toxicity 
induced by PA. 
  Measurement of intracellular calcium (Ca2+) fluorescence by microscopy. 
This evaluation allows demonstrating if Ca
2+ 
alterations occur in cells treated with 
PEs and PA. Since several reports show that Ca
2+ 
alterations can lead to ΔΨm 
collapse and mitochondrial dysfunction (Fan et al., 2013; Hajnoczky et al., 2006; 
Yokoshiki et al., 1996), one possibility is that the selected PEs decreased Ca
2+
 
dysregulation caused by PA. 
 
Moreover, it is necessary to increase the number of independent experiments in all 
experiments if using this model, because n=3 is clearly not enough for this type of 
study. 
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